Literature DB >> 3090146

Trypanosoma cruzi: characterization and isolation of a 57/51,000 m.w. surface glycoprotein (GP57/51) expressed by epimastigotes and bloodstream trypomastigotes.

J Scharfstein, M Schechter, M Senna, J M Peralta, L Mendonça-Previato, M A Miles.   

Abstract

We have recently described the application of a purified glycoprotein of 25,000 Mr (GP25) of Trypanosoma cruzi in serodiagnosis of Chagas' disease. Purified GP25 lacks appreciable immunogenicity in some animal species, in spite of being generally antigenic to parasitized hosts. The underlying cause for these contrasting observations has not been determined, but it may relate to the drastic extraction conditions used in the original isolation procedure, and possible damage inflicted to the native form of this antigen. This report describes the molecular properties of a GP25-related primary antigen, and a fast performance liquid chromatographic (FPLC) procedure to attain its isolation under gentle conditions. The expression of GP25-related antigen by epimastigotes or bloodstream forms was investigated with a high-affinity monoclonal antibody to GP25, SC11G10, as well as with monospecific antisera to GP25. Immunochemical analysis of Nonidet P-40 lysates supplemented with protease inhibitors indicated that GP25 is not synthesized as such; instead, a 57,000 Mr component (GP57) was identified as the primary antigen product. Partial enzymatic conversion to GP25 was observed when inhibitors were deliberately omitted from cell extracts. Most significantly, GP57 was established as the primary biosynthetic product in [35S]-labeled bloodstream trypomastigotes after immunoprecipitation with SC11G10 antibody. This analysis when applied to metabolically labeled epimastigotes has consistently revealed a minor antigen component of 51,000 Mr (GP51), in addition to GP57. The former was identified as the antigenically related product exposed at the parasite cell surface after external radioiodination of viable trypanosomes. Access to the native form of this widely distributed surface glycoprotein should stimulate the investigation of functional and structural aspects of its immunologic activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3090146

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Use of full-length recombinant calflagin and its c fragment for improvement of diagnosis of Trypanosoma cruzi infection.

Authors:  Iván S Marcipar; Cintia Roodveldt; Gerardo Corradi; María L Cabeza; Maria Edileuza F Brito; Lucile M Floeter Winter; Alberto J Marcipar; Ariel M Silber
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

2.  Design, construction, and evaluation of a specific chimeric antigen to diagnose chagasic infection.

Authors:  Sebastián Aguirre; Ariel M Silber; Maria Edileuza F Brito; María E Ribone; Claudia M Lagier; Iván S Marcipar
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

Review 3.  Carbohydrate immunity in American trypanosomiasis.

Authors:  L R Travassos; I C Almeida
Journal:  Springer Semin Immunopathol       Date:  1993

4.  Investigation of the substrate specificity of cruzipain, the major cysteine proteinase of Trypanosoma cruzi, through the use of cystatin-derived substrates and inhibitors.

Authors:  C Serveau; G Lalmanach; M A Juliano; J Scharfstein; L Juliano; F Gauthier
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

5.  Alterations in the surface charge of heart muscle cells during interaction with Trypanosoma cruzi.

Authors:  M de N Soeiro; F Costa e Silva Filho; M de N Leal de Meirelles
Journal:  Cell Biophys       Date:  1995-02

6.  Nitro/nitrosyl-ruthenium complexes are potent and selective anti-Trypanosoma cruzi agents causing autophagy and necrotic parasite death.

Authors:  Tanira M Bastos; Marília I F Barbosa; Monize M da Silva; José W da C Júnior; Cássio S Meira; Elisalva T Guimaraes; Javier Ellena; Diogo R M Moreira; Alzir A Batista; Milena B P Soares
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

7.  The major cysteine proteinase (cruzipain) from Trypanosoma cruzi is antigenic in human infections.

Authors:  J Martinez; O Campetella; A C Frasch; J J Cazzulo
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

8.  Further characterization of Trypanosoma cruzi GP57/51 as the major antigen expressed by differentiating epimastigotes.

Authors:  M C Bonaldo; J Scharfstein; A C Murta; S Goldenberg
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

9.  Serodiagnosis of Chagas' disease using monoclonal antibody against Trypanosoma cruzi-specific Mr 25,000 antigen.

Authors:  H Tachibana; K Nagakura; Y Kaneda
Journal:  Parasitol Res       Date:  1988       Impact factor: 2.289

10.  Inhibition of HIV-1 replication in human monocyte-derived macrophages by parasite Trypanosoma cruzi.

Authors:  Guadalupe Andreani; Ana M Celentano; María E Solana; Silvia I Cazorla; Emilio L Malchiodi; Liliana A Martínez Peralta; Guillermina L Dolcini
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.